Genentech's lung cancer drug Alecensa received FDA's conditional approval for the treatment of ALK-positive lung cancer. Alecensa was found to reduce lung tumors of 44 percent of the 138 patients with benefits lasting an average of 11 months.
Genentech's lung cancer drug Alecensa received FDA's conditional approval for the treatment of ALK-positive lung cancer. Alecensa was found to reduce lung tumors of 44 percent of the 138 patients with benefits lasting an average of 11 months.
Share this Article
Recommended